Profile Image

Professor Joerg Mattes

Chair - Paediatrics & Child Health

School of Medicine and Public Health (Immunology and Microbiology)

Career Summary

Biography

My research has focused on the pathogenesis of asthma, allergies and respiratory infections. The major sequence of recent projects undertaken in this area has involved epidemiological studies (e.g. birth cohort studies on the effect of asthma during pregnancy), clinical studies (e.g. improved diagnostic algorithm for peanut allergy employing exhaled nitric oxide), studies in mouse models of experimental asthma and rhinovirus infection (e.g. role of micro(mi)RNAs and TRAIL/MID1/PP2A). I have established the NSW Children and Infants lung function CEntre (NICE) in order to investigate the origins of asthma in early life on a physiological, cellular and molecular level. I have published in high impact journals [e.g. J Exp Med, Nat Med, JACI, PNAS] highlighting the significance of my scientific contributions to the field since 1998. The work has also received several prizes and awards at scientific meetings. I am regular reviewer of international medical journals and national and international grant funding bodies and editor of the Asthma & Allergic disorders section of BMC Pulmonary Medicine. I am convener of the Special Interest Group Asthma, Thoracic Society of Australia and New Zealand.

I am Head of Experimental and Translational Respiratory Medicine that employs a wide range of state-of-the-art experimental disease models (e.g. rhinovirus infection in mice, transgenic mouse models, eosinophilic oesophagitis & food allergy mouse models), molecular cutting-edge techniques (miRNA arraying, siRNA-mediated inhibition in vivo), ex vivo tissue culture systems (culturing of PBMCs, infection of airway epithelial cells), infant and pre-schooler lung function testing (e.g. the raised-volume rapid thoracoabdominal compression technique, multiple breath washout, forced oscillation technique, FeNO). We have successful national and international collaborations that are documented by publications in the highest-ranking medical science journals. 

I am a Paediatric Respiratory and Sleep Medicine physician (FRACP) and was clinically very active throughout my career. I was trained at the University Children's Hospital Freiburg, Germany from 1996 to 2005 including a Research Fellowship (German Research Council) at the John Curtin School of Medical Research, ANU, Canberra from 1999 to 2001. I have completed a M.D. degree in Cardiology (1999, University of Hamburg) and a Doctor habilitatus in Paediatrics (2005, University of Freiburg, premier Research higher Degree qualification for medical doctors in Germany). Based at the Newcastle Children's Hospital, I provide specialist services as a Consultant in Paediatric Respiratory and Sleep Medicine across the entire Northern NSW Child Health Network (Kaleidoscope). I am the clinical Director of the Paediatric lung function service and member of the Kaleidoscope Strategic Leadership Team.

In March 2011 I was appointed as the Chair and Discipline Lead of Paediatrics & Child Health at the University of Newcastle. I am the Course Coordinator for the Women, Children, and Adolescent Course (WACH) of Joint Medical Program, Year 4. I have recently authored the Neonatology and the Paediatrics Chapter (eBook) in Talley and O'Connor's Clinical Examination: A Systematic Guide to Physical Diagnosis, 7th Edition, a bestselling title for over 25 years among student clinicians.

I am a translational researcher with an internationally recognized expertise in both experimental and clinical Paediatric Respiratory Medicine as well as a scholarly teacher with the vision to promote self-improving health care to children and their families through excellence in research & education.

Research Expertise
Role of microRNA in antiviral responses, Role of microRNA in the pathogenesis of asthma, Role of TRAIL in allergic airways disease, Asthma in early life. 

Qualifications

  • Habilitation (European Equiv to Doctor of Sc), University of Freiburg - Germany
  • Doctor of Medicine, University of Hamburg - Germany

Keywords

  • Asthma and wheezing
  • Immunology
  • Infant lung function
  • Paediatrics
  • Respiratory Diseases
  • Rhinovirus
  • Virology

Languages

  • German (Fluent)

Fields of Research

Code Description Percentage
060499 Genetics not elsewhere classified 10
110399 Clinical Sciences not elsewhere classified 25
110799 Immunology not elsewhere classified 65

Professional Experience

UON Appointment

Title Organisation / Department
Chair - Paediatrics & Child Health University of Newcastle
School of Medicine and Public Health
Australia

Academic appointment

Dates Title Organisation / Department
1/12/2007 - 1/12/2011 Health Professional Research Fellowship (Part-time)

NHMRC - Early Career Fellowships (Formerly Postdoctoral Training Fellowships)

University of Newcastle
School of Medicine and Public Health
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (6 outputs)

Year Citation Altmetrics Link
2015 Maltby S, Plank M, Ptaschinski C, Mattes J, Foster PS, 'Microrna function in mast cell biology: protocols to characterize and modulate microrna expression', , Humana Press Inc. 287-304 (2015)

MicroRNAs (miRNAs) are small noncoding RNA molecules that can modulate mRNA levels through RNA-induced silencing complex (RISC)-mediated degradation. Recognition of target mRNAs o... [more]

MicroRNAs (miRNAs) are small noncoding RNA molecules that can modulate mRNA levels through RNA-induced silencing complex (RISC)-mediated degradation. Recognition of target mRNAs occurs through imperfect base pairing between an miRNA and its target, meaning that each miRNA can target a number of different mRNAs to modulate gene expression. miRNAs have been proposed as novel therapeutic targets and many studies are aimed at characterizing miRNA expression patterns and functions within a range of cell types. To date, limited research has focused on the function of miRNAs specifi cally in mast cells; however, this is an emerging fi eld. In this chapter, we will briefl y overview miRNA synthesis and function and the current understanding of miRNAs in hematopoietic development and immune function, emphasizing studies related to mast cell biology. The chapter will conclude with fundamental techniques used in miRNA studies, including RNA isolation, real-time PCR and microarray approaches for quantifi cation of miRNA expression levels, and antagomir design to interfere with miRNA function.

DOI 10.1007/978-1-4939-1568-2_18,
Co-authors Paul Foster, Steven Maltby
2015 Maltby S, Plank M, Ptaschinski C, Mattes J, Foster PS, 'Microrna function in mast cell biology: protocols to characterize and modulate microrna expression', , Humana Press Inc. 287-304 (2015)
DOI 10.1007/978-1-4939-1568-2_18,
Co-authors Paul Foster, Steven Maltby
2015 Maltby S, Plank M, Ptaschinski C, Mattes J, Foster PS, 'MicroRNA function in mast cell biology: protocols to characterize and modulate microRNA expression', 287-304 (2015)

MicroRNAs (miRNAs) are small noncoding RNA molecules that can modulate mRNA levels through RNA-induced silencing complex (RISC)-mediated degradation. Recognition of target mRNAs o... [more]

MicroRNAs (miRNAs) are small noncoding RNA molecules that can modulate mRNA levels through RNA-induced silencing complex (RISC)-mediated degradation. Recognition of target mRNAs occurs through imperfect base pairing between an miRNA and its target, meaning that each miRNA can target a number of different mRNAs to modulate gene expression. miRNAs have been proposed as novel therapeutic targets and many studies are aimed at characterizing miRNA expression patterns and functions within a range of cell types. To date, limited research has focused on the function of miRNAs specifically in mast cells; however, this is an emerging field. In this chapter, we will briefly overview miRNA synthesis and function and the current understanding of miRNAs in hematopoietic development and immune function, emphasizing studies related to mast cell biology. The chapter will conclude with fundamental techniques used in miRNA studies, including RNA isolation, real-time PCR and microarray approaches for quantification of miRNA expression levels, and antagomir design to interfere with miRNA function.

DOI 10.1007/978-1-4939-1568-2_18
Co-authors Steven Maltby, Paul Foster
2015 Maltby S, Plank M, Ptaschinski C, Mattes J, Foster PS, 'MicroRNA function in mast cell biology: protocols to characterize and modulate microRNA expression', 287-304 (2015)

MicroRNAs (miRNAs) are small noncoding RNA molecules that can modulate mRNA levels through RNA-induced silencing complex (RISC)-mediated degradation. Recognition of target mRNAs o... [more]

MicroRNAs (miRNAs) are small noncoding RNA molecules that can modulate mRNA levels through RNA-induced silencing complex (RISC)-mediated degradation. Recognition of target mRNAs occurs through imperfect base pairing between an miRNA and its target, meaning that each miRNA can target a number of different mRNAs to modulate gene expression. miRNAs have been proposed as novel therapeutic targets and many studies are aimed at characterizing miRNA expression patterns and functions within a range of cell types. To date, limited research has focused on the function of miRNAs specifically in mast cells; however, this is an emerging field. In this chapter, we will briefly overview miRNA synthesis and function and the current understanding of miRNAs in hematopoietic development and immune function, emphasizing studies related to mast cell biology. The chapter will conclude with fundamental techniques used in miRNA studies, including RNA isolation, real-time PCR and microarray approaches for quantification of miRNA expression levels, and antagomir design to interfere with miRNA function.

DOI 10.1007/978-1-4939-1568-2_18
Co-authors Paul Foster, Steven Maltby
2015 Maltby S, Plank M, Ptaschinski C, Mattes J, Foster PS, 'MicroRNA function in mast cell biology: protocols to characterize and modulate microRNA expression.', 287-304 (2015)
DOI 10.1007/978-1-4939-1568-2_18
Co-authors Steven Maltby, Paul Foster
2013 Lee JJ, Ptaschinski C, Plank M, Mattes J, Foster PS, Balla KM, et al., 'Emerging Concepts', Eosinophils in Health and Disease, Academic Press, London 607-641 (2013) [B1]
DOI 10.1016/B978-0-12-394385-9.00016-X
Co-authors Paul Foster
Show 3 more chapters

Journal article (76 outputs)

Year Citation Altmetrics Link
2015 Li JJ, Tay HL, Maltby S, Xiang Y, Eyers F, Hatchwell L, et al., 'MicroRNA-9 regulates steroid-resistant airway hyperresponsiveness by reducing protein phosphatase 2A activity', Journal of Allergy and Clinical Immunology, 136 462-473 (2015)

Background Steroid-resistant asthma is a major clinical problem that is linked to activation of innate immune cells. Levels of IFN-¿ and LPS are often increased in these patients... [more]

Background Steroid-resistant asthma is a major clinical problem that is linked to activation of innate immune cells. Levels of IFN-¿ and LPS are often increased in these patients. Cooperative signaling between IFN-¿/LPS induces macrophage-dependent steroid-resistant airway hyperresponsiveness (AHR) in mouse models. MicroRNAs (miRs) are small noncoding RNAs that regulate the function of innate immune cells by controlling mRNA stability and translation. Their role in regulating glucocorticoid responsiveness and AHR remains unexplored. Objective IFN-¿ and LPS synergistically increase the expression of miR-9 in macrophages and lung tissue, suggesting a role in the mechanisms of steroid resistance. Here we demonstrate the role of miR-9 in IFN-¿/LPS-induced inhibition of dexamethasone (DEX) signaling in macrophages and in induction of steroid-resistant AHR. Methods MiRNA-9 expression was assessed by means of quantitative RT-PCR. Putative miR-9 targets were determined in silico and confirmed in luciferase reporter assays. miR-9 function was inhibited with sequence-specific antagomirs. The efficacy of DEX was assessed by quantifying glucocorticoid receptor (GR) cellular localization, protein phosphatase 2A (PP2A) activity, and AHR. Results Exposure of pulmonary macrophages to IFN-¿/LPS synergistically induced miR-9 expression; reduced levels of its target transcript, protein phosphatase 2 regulatory subunit B (B56) d isoform; attenuated PP2A activity; and inhibited DEX-induced GR nuclear translocation. Inhibition of miR-9 increased both PP2A activity and GR nuclear translocation in macrophages and restored steroid sensitivity in multiple models of steroid-resistant AHR. Pharmacologic activation of PP2A restored DEX efficacy and inhibited AHR. MiR-9 expression was increased in sputum of patients with neutrophilic but not those with eosinophilic asthma. Conclusion MiR-9 regulates GR signaling and steroid-resistant AHR. Targeting miR-9 function might be a novel approach for the treatment of steroid-resistant asthma.

DOI 10.1016/j.jaci.2014.11.044
Citations Scopus - 1
2015 Schilter HC, Collison A, Russo RC, Foot JS, Yow TT, Vieira AT, et al., 'Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration', Respiratory Research, 16 (2015)

Background and purpose: The persistent influx of neutrophils into the lung and subsequent tissue damage are characteristics of COPD, cystic fibrosis and acute lung inflammation. V... [more]

Background and purpose: The persistent influx of neutrophils into the lung and subsequent tissue damage are characteristics of COPD, cystic fibrosis and acute lung inflammation. VAP-1/SSAO is an endothelial bound adhesion molecule with amine oxidase activity that is reported to be involved in neutrophil egress from the microvasculature during inflammation. This study explored the role of VAP-1/SSAO in neutrophilic lung mediated diseases and examined the therapeutic potential of the selective inhibitor PXS-4728A. Methods: Mice treated with PXS-4728A underwent intra-vital microscopy visualization of the cremaster muscle upon CXCL1/KC stimulation. LPS inflammation, Klebsiella pneumoniae infection, cecal ligation and puncture as well as rhinovirus exacerbated asthma models were also assessed using PXS-4728A. Results: Selective VAP-1/SSAO inhibition by PXS-4728A diminished leukocyte rolling and adherence induced by CXCL1/KC. Inhibition of VAP-1/SSAO also dampened the migration of neutrophils to the lungs in response to LPS, Klebsiella pneumoniae lung infection and CLP induced sepsis; whilst still allowing for normal neutrophil defense function, resulting in increased survival. The functional effects of this inhibition were demonstrated in the RV exacerbated asthma model, with a reduction in cellular infiltrate correlating with a reduction in airways hyperractivity. Conclusions and implications: This study demonstrates that the endothelial cell ligand VAP-1/SSAO contributes to the migration of neutrophils during acute lung inflammation, pulmonary infection and airway hyperractivity. These results highlight the potential of inhibiting of VAP-1/SSAO enzymatic function, by PXS-4728A, as a novel therapeutic approach in lung diseases that are characterized by neutrophilic pattern of inflammation.

DOI 10.1186/s12931-015-0200-z
2015 Tay HL, Kaiko GE, Plank M, Li J, Maltby S, Essilfie AT, et al., 'Antagonism of miR-328 increases the antimicrobial function of macrophages and neutrophils and rapid clearance of non-typeable Haemophilus influenzae (NTHi) from infected lung.', PLoS pathogens, 11 e1004549 (2015)
DOI 10.1371/journal.ppat.1004549
Co-authors Steven Maltby, Philip Hansbro, Paul Foster
2015 Mandaliya PH, Morten M, Kumar R, James A, Deshpande A, Murphy VE, et al., 'Ventilation inhomogeneities in children with congenital thoracic malformations.', BMC Pulm Med, 15 25 (2015)
DOI 10.1186/s12890-015-0023-1
Co-authors Peter Gibson, Vanessa Murphy
2015 Li JJ, Tay HL, Maltby S, Xiang Y, Eyers F, Hatchwell L, et al., 'MicroRNA-9 regulates steroid-resistant airway hyperresponsiveness by reducing protein phosphatase 2A activity.', J Allergy Clin Immunol, 136 462-473 (2015)
DOI 10.1016/j.jaci.2014.11.044
Co-authors Steven Maltby, Paul Foster
2015 Girkin J, Hatchwell L, Foster P, Johnston SL, Bartlett N, Collison A, Mattes J, 'CCL7 and IRF-7 Mediate Hallmark Inflammatory and IFN Responses following Rhinovirus 1B Infection.', J Immunol, 194 4924-4930 (2015)
DOI 10.4049/jimmunol.1401362
Co-authors Nathan Bartlett, Paul Foster
2015 Thorburn AN, McKenzie CI, Shen S, Stanley D, Macia L, Mason LJ, et al., 'Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites.', Nat Commun, 6 7320 (2015)
DOI 10.1038/ncomms8320
Co-authors Peter Gibson, Vanessa Murphy, Lisa Wood
2015 Hatchwell L, Collison A, Girkin J, Parsons K, Li J, Zhang J, et al., 'Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia.', Thorax, 70 854-861 (2015)
DOI 10.1136/thoraxjnl-2014-205465
Co-authors Nathan Bartlett, Paul Foster, Darryl Knight
2014 Starkey MR, Nguyen DH, Essilfie AT, Kim RY, Hatchwell LM, Collison AM, et al., 'Tumor necrosis factor-related apoptosis-inducing ligand translates neonatal respiratory infection into chronic lung disease.', Mucosal Immunol, 7 478-488 (2014) [C1]
DOI 10.1038/mi.2013.65
Citations Scopus - 1
Co-authors Paul Foster, Jay Horvat, Malcolm Starkey, Philip Hansbro
2014 Mattes J, Murphy VE, Powell H, Gibson PG, 'Prenatal origins of bronchiolitis: Protective effect of optimised asthma management during pregnancy', Thorax, 69 383-384 (2014) [C1]

Objective Maternal asthma is the most common chronic disease complicating pregnancy and is a risk factor for bronchiolitis in infancy. Recurrent episodes of bronchiolitis are stro... [more]

Objective Maternal asthma is the most common chronic disease complicating pregnancy and is a risk factor for bronchiolitis in infancy. Recurrent episodes of bronchiolitis are strongly associated with the development of childhood asthma. Methods We conducted a follow-up study of infants born to women with asthma who completed a double-blind randomised controlled trial during pregnancy. In this trial, pregnant women with asthma were assigned to treatment adjustment by an algorithm using clinical symptoms (clinical group) or the fraction of exhaled nitric oxide (FeNO group) and we showed that the FeNO group had significantly lower asthma exacerbation rates in pregnancy. Results 146 infants attended the 12-month follow-up visit. Infants born to mothers from the FeNO group were significantly less likely to have recurrent episodes of bronchiolitis in the first year of life (OR 0.08, 95% CI 0.01 to 0.62; p=0.016) as compared with the clinical group. Conclusions Optimised management of asthma during pregnancy may reduce recurrent episodes of bronchiolitis in infancy, which could potentially modulate the risk to develop or the severity of emerging childhood asthma.

DOI 10.1136/thoraxjnl-2013-203388
Citations Scopus - 6Web of Science - 3
Co-authors Vanessa Murphy, Peter Gibson
2014 Mattes J, Gibson PG, 'The early origins of copd in severe asthma: The one thing that leads to another or the two things that come together?', Thorax, 69 789-790 (2014)
DOI 10.1136/thoraxjnl-2013-204815
Co-authors Peter Gibson
2014 Hatchwell L, Girkin J, Morten M, Collison A, Mattes J, Foster PS, et al., 'Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease¿by modulating protein phosphatase 2A', Journal of Allergy and Clinical Immunology, (2014) [C1]

Background: ß-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinnin... [more]

Background: ß-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinning mechanisms remain poorly understood. Recently, a direct interaction between formoterol and protein phosphatase 2A (PP2A) has been described in¿vitro. Objective: We sought to elucidate the molecular mechanisms by which ß-agonists exert anti-inflammatory effects in allergen-driven and rhinovirus 1B-exacerbated allergic airways disease (AAD). Methods: Mice were sensitized and then challenged with house dust mite to induce AAD while receiving treatment with salmeterol, formoterol, or salbutamol. Mice were also infected with rhinovirus 1B to exacerbate lung inflammation and therapeutically administered salmeterol, dexamethasone, or the PP2A-activating drug (S)-2-amino-4-(4-[heptyloxy]phenyl)-2-methylbutan-1-ol (AAL[S]). Results: Systemic or intranasal administration of salmeterol protected against the development of allergen- and rhinovirus-induced airway hyperreactivity and decreased eosinophil recruitment to the lungs as effectively as dexamethasone. Formoterol and salbutamol also showed anti-inflammatory properties. Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor ¿B subunits in the lungs. The anti-inflammatory effect of salmeterol was blocked by targeting the catalytic subunit of PP2A with small RNA interference. Conversely, increasing PP2A activity with AAL(S) abolished rhinovirus-induced airway hyperreactivity, eosinophil influx, and CCL11, CCL20, and CXCL2 expression. Salmeterol also directly activated immunoprecipitated PP2A in¿vitro isolated from human airway epithelial cells. Conclusions: Salmeterol exerts anti-inflammatory effects by increasing PP2A activity in AAD and rhinovirus-induced lung inflammation, which might potentially account for some of its clinical benefits. © 2013 American Academy of Allergy, Asthma & Immunology.

DOI 10.1016/j.jaci.2013.11.014
Citations Scopus - 6Web of Science - 4
Co-authors Paul Foster, Nikki Verrills, Matt Dun
2014 Collison AM, Sokulsky LA, Sherrill JD, Nightingale S, Hatchwell L, Talley NJ, et al., 'TNF-related apoptosis-inducing ligand (TRAIL) regulates midline-1, thymic stromal lymphopoietin, inflammation, andremodeling in experimental eosinophilic esophagitis', Journal of Allergy and Clinical Immunology, (2014)

Background: Eosinophilic esophagitis (EoE) is an inflammatory disorder of the esophagus defined by eosinophil infiltration and tissue remodeling with resulting symptoms of esophag... [more]

Background: Eosinophilic esophagitis (EoE) is an inflammatory disorder of the esophagus defined by eosinophil infiltration and tissue remodeling with resulting symptoms of esophageal dysfunction. TNF-related apoptosis-inducing ligand (TRAIL) promotes inflammation through upregulation of the E3 ubiquitin-ligase midline-1 (MID1), which binds to and deactivates the catalytic subunit of protein phosphatase 2Ac, resulting in increased nuclear factor ¿B activation. Objective: We sought to elucidate the role of TRAIL in EoE. Methods: We used Aspergillus fumigatus to induce EoE in TRAIL-sufficient (wild-type) and TRAIL-deficient (TRAIL-/-) mice and targeted MID1 in the esophagus with small interfering RNA. We also treated mice with recombinant thymic stromal lymphopoietin (TSLP) and TRAIL. Results: TRAIL deficiency and MID1 silencing with small interfering RNA reduced esophageal eosinophil and mast cell numbers and protected against esophageal circumference enlargement, muscularis externa thickening, and collagen deposition. MID1 expression and nuclear factor ¿B activation were reduced in TRAIL-/- mice, whereas protein phosphatase 2Ac levels were increased compared with those seen in wild-type control mice. This was associated with reduced expression of CCL24, CCL11, CCL20, IL-5, IL-13, IL-25, TGFB, and TSLP. Treatment with TSLP reconstituted hallmark features of EoE in TRAIL-/- mice and recombinant TRAIL induced esophageal TSLP expression invivo in the absence of allergen. Post hoc analysis of gene array data demonstrated significant upregulation of TRAIL and MID1 in a cohort of children withEoE compared with that seen in controls. Conclusion: TRAIL regulates MID1 and TSLP, inflammation, fibrosis, smooth muscle hypertrophy, and expression ofinflammatory effector chemokines and cytokines inexperimental EoE.

DOI 10.1016/j.jaci.2015.03.031
Co-authors Marjorie Walker, Nicholas Talley
2014 Tay HL, Plank M, Collison A, Mattes J, Kumar RK, Foster PS, 'MicroRNA: Potential biomarkers and therapeutic targets for allergic asthma?', Annals of Medicine, 46 633-639 (2014) [C1]

MicroRNAs are small non-coding RNAs that bind to multiple target mRNAs to control gene expression post-transcriptionally by inhibiting translation. In mammalian cells, microRNAs p... [more]

MicroRNAs are small non-coding RNAs that bind to multiple target mRNAs to control gene expression post-transcriptionally by inhibiting translation. In mammalian cells, microRNAs play important roles in a diverse array of cellular processes (e.g. cell proliferation and differentiation). However, alterations in their levels may compromise cellular function, predisposing to disease. In this review, we discuss microRNAs that have been linked with pathogenesis of asthma and propose functional roles in the regulation of disease. MicroRNAs have the potential to be biomarkers for asthma and provide the platform for the development of new classes of therapeutic compounds.

DOI 10.3109/07853890.2014.958196
Citations Scopus - 1Web of Science - 1
Co-authors Paul Foster
2014 Murphy VE, Mattes J, Powell H, Baines KJ, Gibson PG, 'Respiratory viral infections in pregnant women with asthma are associated with wheezing in the first 12 months of life', Pediatric Allergy and Immunology, 25 151-158 (2014) [C1]

Background: There are few studies investigating the relationship between respiratory viral infection in pregnancy and asthma in the offspring, and none among mothers with asthma. ... [more]

Background: There are few studies investigating the relationship between respiratory viral infection in pregnancy and asthma in the offspring, and none among mothers with asthma. Infants of mothers with asthma are more likely to wheeze and have a higher risk of developing asthma than infants of non-asthmatic mothers. Methods: A prospective cohort study of viral infection in pregnancy was conducted between 2007 and 2009, and a subgroup of infants of mothers with asthma was followed up at 6 and 12 months of age. During common colds, nasal and throat swabs were collected from mothers and respiratory viruses detected by polymerase chain reaction. Respiratory health of infants was assessed by parent-completed questionnaire. Results: Twelve-month-old infants whose mothers had confirmed viral infections in pregnancy (n = 26) reported more frequent wheeze (40% had 4-12 wheeze attacks compared with 0%), sleep disturbed by wheeze (1 night per week or more in 60% vs. 11%), beta agonist treatment for wheeze (27% vs. 0%), prolonged colds (2 wk or longer 31% vs. 0%), more eczema (40% vs. 6.3%), and parent-perceived asthma (32% vs. 0%), compared with infants whose mothers had common colds without laboratory-confirmed viral infection (n = 16). Conclusions: This study demonstrates a relationship between maternal respiratory viral infection in pregnancy and wheezing illness in infants of mothers with asthma. Viral infections are the most common cause of asthma exacerbations in pregnancy, and infants of asthmatic mothers are at increased risk of asthma themselves. Further research is needed to elucidate the mechanisms involved. © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

DOI 10.1111/pai.12156
Citations Scopus - 2Web of Science - 2
Co-authors Peter Gibson, Vanessa Murphy, Katherine Baines
2014 Preece K, Bhatia R, Belcher J, Patchett K, McElduff P, Collison A, Mattes J, 'The fraction of exhaled nitric oxide improves prediction of clinical allergic reaction to peanut challenge in children', CLINICAL AND EXPERIMENTAL ALLERGY, 44 371-380 (2014) [C1]
DOI 10.1111/cea.12258
Co-authors Patrick Mcelduff
2014 Pinnock R, Monagle P, Couper J, Wright I, Asher I, Jones P, et al., 'Dedicated paediatric teaching remains critical to the undergraduate medical curriculum', JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 50 949-951 (2014) [C3]
DOI 10.1111/jpc.12775
2014 Wark PAB, Murphy V, Mattes J, 'The interaction between mother and fetus and the development of allergic asthma', Expert Review of Respiratory Medicine, 8 57-66 (2014) [C1]

The rising prevalence of asthma and atopic disease in industrialized countries in the last 50 years has raised important questions about how and why the disease develops in suscep... [more]

The rising prevalence of asthma and atopic disease in industrialized countries in the last 50 years has raised important questions about how and why the disease develops in susceptible populations. Most asthma begins in childhood in association with allergic sensitization and the development of a TH2 phenotype. It is recognized that asthma arises in the context of a complex interaction between genetic factors and the evolving immune system of the infant and the environment to which it is exposed, which now includes its in utero exposure. Early life exposures that lead to allergen sensitization and airway damage, especially in the form of viral respiratory tract infections, may lead to disease induction that commence the process that leads in some to asthma. Asthma models and early life observations suggest that repeated exposure to allergens and viral infection perpetuate a state of chronic airway inflammation leading to a maladaptive innate immune response that fails to resolve, characterized by chronic airway inflammation, airway remodeling and airway hyperresponsiveness. This article will concentrate on the development of asthma in the context of early life and maternal influences, including the effect of asthma on both the fetus and the mother. © 2014 Informa UK Ltd.

DOI 10.1586/17476348.2014.848795
Citations Scopus - 4Web of Science - 4
Co-authors Vanessa Murphy, Peter Wark
2014 Mattes J, Gibson PG, 'The early origins of copd in severe asthma: The one thing that leads to another or the two things that come together?', Thorax, 69 789-790 (2014) [C3]
DOI 10.1136/thoraxjnl-2013-204815
Citations Scopus - 3Web of Science - 3
Co-authors Peter Gibson
2014 Hansbro PM, Starkey MR, Mattes J, Horvat JC, 'Pulmonary immunity during respiratory infections in early life and the development of severe asthma', Annals of the American Thoracic Society, 11 S297-S302 (2014) [C1]

Asthma affects 10% of the population in Westernized countries, being most common in children. It is a heterogeneous condition characterized by chronic allergic airway inflammation... [more]

Asthma affects 10% of the population in Westernized countries, being most common in children. It is a heterogeneous condition characterized by chronic allergic airway inflammation, mucus hypersecretion, and airway hyperresponsiveness (AHR) to normally innocuous antigens. Combination therapies with inhaled corticosteroids and bronchodilators effectively manage mild to moderate asthma, but there are no cures, and patients with severe asthma do not respond to these treatments. The inception of asthma is linked to respiratory viral (respiratory syncytial virus, rhinovirus) and bacterial (Chlamydia, Mycoplasma) infections. The examination of mouse models of early-life infections and allergic airway disease (AAD) provides valuable insights into the mechanisms of disease inception that may lead to the development of more effective therapeutics. For example, early-life, but not adult, Chlamydia respiratory infections in mice permanently modify immunity and lung physiology. This increases the severity of AAD by promoting IL-13 expression, mucus hypersecretion, and AHR. We have identified novel roles for tumor necrosis factor-related apoptosisinducing ligand (TRAIL) and IL-13 in promoting infection-induced pathology in early life and subsequent chronic lung disease. Genetic deletion of TRAIL or IL-13 variously protected against neonatal infection-induced inflammation, mucus hypersecretion, altered lung structure, AHR, and impaired lung function. Therapeutic neutralization of these factors prevented infection-induced severe AAD. Other novel mechanisms and avenues for intervention are also being explored. Such studies indicate the immunological mechanisms that may underpin the association between early-life respiratory infections and the development of more severe asthma and may facilitate the development of tailored preventions and treatments.

DOI 10.1513/AnnalsATS.201402-086AW
Citations Scopus - 2
Co-authors Philip Hansbro, Jay Horvat, Malcolm Starkey
2014 Gunawardhana LP, Baines KJ, Mattes J, Murphy VE, Simpson JL, Gibson PG, 'Differential DNA methylation profiles of infants exposed to maternal asthma during pregnancy', Pediatric Pulmonology, 49 852-862 (2014) [C1]

Background Asthma is a complex disease that involves both genetic factors and environmental exposures. Aberrant epigenetic modifications, such as DNA methylation, may be important... [more]

Background Asthma is a complex disease that involves both genetic factors and environmental exposures. Aberrant epigenetic modifications, such as DNA methylation, may be important in asthma development. Fetal exposure to maternal asthma during critical periods of in utero development may lead to epigenetic alterations that predispose infants to a greater risk of developing asthma themselves. We investigated alterations in the DNA methylation profile of peripheral blood from infants exposed to maternal asthma during pregnancy. Methods Peripheral blood was collected from 12-month-old infants born to women with (n = 25) and without (n = 15) doctor diagnosed asthma during pregnancy. Genomic DNA was extracted, bisulfite converted, and hybridized to Infinium Methylation 27 arrays (Illumina), containing over27,000 CpGs from 14,495 genes. CpG loci in only autosomal genes were classified as differentially methylated at the 99% level (P < 0.01, |DiffScore| > 22 and delta beta >0.06). Results There were 70 CpG loci, corresponding to 67 genes that were significantly differentially methylated. Twelve CpG loci (11 genes) showed greater than 10% comparative difference in DNA methylation, including hyper-methylated loci of FAM181A, MRI1, PIWIL1, CHFR, DEFA1, MRPL28, AURKA, and hypo-methylated loci of NALP1L5, MAP8KIP3, ACAT2, and PM20D1 in maternal asthma. Methylation of MAPK8IP3 was significantly negatively correlated with maternal blood eosinophils (r = -0.38; P = 0.022), maternal eNO (r = -0.44; P = 0.005), and maternal serum total IgE (r = -0.39, P = 0.015). Methylation of AURKA negatively correlated with maternal hemoglobin (r = -0.43; P = 0.008), infants height (r = -0.51; P < 0.001) and weight (r = -0.36; P = 0.021). Methylation of PM20D1 was lower in infants born to mothers with asthma on inhaled corticosteroid treatment. Methylation of PM20D1 was lower and MRI1 was higher in infants born to atopic mothers without asthma. Conclusions In an Australian study population, exposure to maternal asthma during pregnancy is associated with differential methylation profiles of infants' peripheral blood DNA, which may act as risk factors for future asthma development. © 2013 Wiley Periodicals, Inc.

DOI 10.1002/ppul.22930
Citations Scopus - 3Web of Science - 2
Co-authors Peter Gibson, Vanessa Murphy, Katherine Baines, Jodie Simpson
2014 Collison A, Li J, Pereira De Siqueira A, Zhang J, Toop HD, Morris JC, et al., 'Tumor necrosis factor-related apoptosis-inducing ligand regulates hallmark features of airways remodeling in allergic airways disease', American Journal of Respiratory Cell and Molecular Biology, 51 86-93 (2014) [C1]

Allergic asthma is a complex disease characterized by acute inflammation of the airways that over time leads to the development of significant structural changes termed remodeling... [more]

Allergic asthma is a complex disease characterized by acute inflammation of the airways that over time leads to the development of significant structural changes termed remodeling. TNF-related apoptosis-inducing ligand (TRAIL) has an important regulatory role in acute allergic airways inflammation through up-regulation of the E3 ubiquitin ligase Midline-1 (MID-1), which limits protein phosphatase 2A (PP2A) activity and downstream dephosphorylation of proinflammatory signaling molecules. The relevance of TRAIL in the development of airways remodeling has yet to be determined. In this study, the lungs of wild-type (WT) BALB/c and Tnfsf10 knockout (TRAIL-/-) mice were chronically exposed to ovalbumin (OVA) for 12 weeks to induce hallmark features of chronic allergic airways disease, including airways hyperreactivity (AHR), subepithelial collagen deposition, goblet cell hyperplasia, and smooth muscle hypertrophy. TRAIL-/- mice were largely protected from the development of AHR and peribronchial eosinophilia and had reduced levels of mast cells in the airways. This correlated with lower levels of cytokines, including IL-4, -5, -10, and -13, and with lower levels of proinflammatory chemokines from cultured cells isolated from the draining lymph nodes. TRAIL-/- mice were also protected from the characteristic features of airways remodeling, including peribronchial fibrosis, smooth muscle hypertrophy, and mucus hypersecretion, which correlated with reduced TGF-ß1 levels in the lungs. MID-1 expression was reduced in TRAIL-/- mice and up-regulated in allergic WT mice. Raising PP2A activity using 2-amino-4-(4-heptyloyphenol)-2-methylbutan-1-ol in allergic WT mice reduced eosinophilia, TGF-ß1, and peribronchial fibrosis. This study shows that TRAIL promotes airways remodeling in an OVA-induced model of chronic allergic airways disease. Targeting TRAIL and its downstream proin flammatory signaling pathway involving PP2A may be of therapeutic bene fit in reducing the hallmark features of airways remodeling observed in chronic allergic airways inflammation. Copyright © 2014 by the American Thoracic Society.

DOI 10.1165/rcmb.2013-0490OC
Citations Scopus - 4Web of Science - 4
Co-authors Paul Foster
2013 de Souza Alves CC, Collison A, Hatchwell L, Plank M, Morten M, Foster PS, et al., 'Inhibiting AKT phosphorylation employing non-cytotoxic anthraquinones ameliorates TH2 mediated allergic airways disease and rhinovirus exacerbation.', PLoS One, 8 e79565 (2013) [C1]
DOI 10.1371/journal.pone.0079565
Citations Scopus - 2Web of Science - 1
Co-authors Paul Foster
2013 Foster PS, Plank MW, Collison AM, Tay HL, Kaiko GE, Li J, et al., 'The emerging role of microRNAs in regulating immune and inflammatory responses in the lung', Immunological Reviews, 253 198-215 (2013) [C1]
Citations Scopus - 9Web of Science - 11
Co-authors Ming Yang, Philip Hansbro, Paul Foster
2013 Barry J, Loh Z, Collison A, Mazzone S, Lalwani A, Zhang V, et al., 'Absence of Toll-IL-1 Receptor 8/Single Immunoglobulin IL-1 Receptor-Related Molecule Reduces House Dust Mite-Induced Allergic Airway Inflammation in Mice', AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 49 481-490 (2013) [C1]
DOI 10.1165/rcmb.2012-0425OC
Citations Scopus - 2Web of Science - 2
Co-authors Paul Foster
2013 Collison AM, Hatchwell LM, Verrills NM, Wark PA, Pereira De Siqueira AL, Tooze MK, et al., 'The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity', Nature Medicine, 19 232-237 (2013) [C1]
Citations Scopus - 33Web of Science - 28
Co-authors Nikki Verrills, Paul Foster, Nathan Bartlett, Peter Wark
2013 Collison A, Siegle JS, Hansbro NG, Kwok C-T, Herbert C, Mattes J, et al., 'Epigenetic changes associated with disease progression in a mouse model of childhood allergic asthma', DISEASE MODELS & MECHANISMS, 6 993-1000 (2013) [C1]
DOI 10.1242/dmm.011247
Citations Scopus - 4Web of Science - 4
Co-authors Paul Foster, Nicole Hansbro
2013 Starkey MR, Essilfie A-T, Horvat JC, Kim RY, Nguyen DH, Beagley KW, et al., 'Constitutive production of IL-13 promotes early-life Chlamydia respiratory infection and allergic airway disease', Mucosal Immunology, 6 569-579 (2013) [C1]
Citations Scopus - 8Web of Science - 4
Co-authors Jay Horvat, Paul Foster, Philip Hansbro, Malcolm Starkey
2012 Starkey MR, Kim RY, Beckett EL, Schilter HC, Shim D, Essilfie A-T, et al., 'Chlamydia muridarum lung infection in infants alters hematopoietic cells to promote allergic airway disease in mice', PLoS One, 7 e42588 (2012) [C1]
Citations Scopus - 7Web of Science - 6
Co-authors Jay Horvat, Philip Hansbro, Malcolm Starkey
2011 Collison AM, Herbert C, Siegle JS, Mattes J, Foster PS, Kumar RK, 'Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target', BMC Pulmonary Medicine, 11 29 (2011) [C1]
Citations Scopus - 43Web of Science - 36
Co-authors Paul Foster
2011 Collison AM, Mattes J, Plank MW, Foster PS, 'Inhibition of house dust mite-induced allergic airways disease by antagonism of microRNA-145 is comparable to glucocorticoid treatment', Journal of Allergy and Clinical Immunology, 128 160-U251 (2011) [C1]
Citations Scopus - 73Web of Science - 59
Co-authors Paul Foster
2011 Weckmann M, Kopp MV, Heinzmann A, Mattes J, 'Haplotypes covering the TNFSF10 gene are associated with bronchial asthma', Pediatric Allergy and Immunology, 22 25-30 (2011) [C1]
DOI 10.1111/j.1399-3038.2010.01027.x
Citations Scopus - 1Web of Science - 1
2009 Tran HA, Song S, Crock PA, Mattes J, Howard K, 'The A, B, C, D of hypercalcaemia in Down syndrome', BMJ Case Reports, (2009) [C1]

Hypercalcaemia in infants with Down syndrome is an uncommon condition with only five previous case reports. The patients often present in the toddler years with the classical tria... [more]

Hypercalcaemia in infants with Down syndrome is an uncommon condition with only five previous case reports. The patients often present in the toddler years with the classical triad of Down syndrome, biochemical hypercalcaemia, and nephrocalcinosis. We present the sixth case and second male with this condition and further review the clinical details of this under-recognised condition and stratify the diagnostic criteria. The management mandates a reduction in calcium intake as a first step. The natural history of the various aspects of this condition is also considered.

DOI 10.1136/bcr.06.2008.0232
2009 Mattes J, Collison AM, Plank MW, Phipps S, Foster PS, 'Antagonism of microRNA-126 suppresses the effector function of T(H)2 cells and the development of allergic airways disease', Proceedings of the National Academy of Sciences of the United States of America, 106 18704-18709 (2009) [C1]
DOI 10.1073/pnas.0905063106
Citations Scopus - 163Web of Science - 153
Co-authors Paul Foster
2009 Collison AM, Foster PS, Mattes J, 'Emerging role of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses', Clinical and Experimental Pharmacology and Physiology, 36 1049-1053 (2009) [C1]
DOI 10.1111/j.1440-1681.2009.05258.x
Citations Scopus - 26Web of Science - 27
Co-authors Paul Foster
2009 Foster PS, Mattes J, 'IL-21 comes of age', Immunology and Cell Biology, 87 359-360 (2009) [C2]
DOI 10.1038/icb.2009.33
Co-authors Paul Foster
2009 Phipps S, Lam CE, Kaiko GE, Foo A, Collison AM, Mattes J, et al., 'Toll/IL-1 signaling is critical for house dust mite-specific Th1 and Th2 responses', American Journal of Respiratory and Critical Care Medicine, 179 883-893 (2009) [C1]
DOI 10.1164/rccm.200806-974oc
Citations Scopus - 92Web of Science - 92
Co-authors Paul Foster
2008 Mattes J, Collison AM, Foster PS, 'Emerging role of microRNAs in disease pathogenesis and strategies for therapeutic modulation', Current Opinion in Molecular Therapeutics, 10 150-157 (2008) [C1]
Citations Scopus - 36Web of Science - 32
Co-authors Paul Foster
2008 Yang M, Mattes J, 'Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs', Pharmacology & Therapeutics, 117 94-104 (2008) [C1]
DOI 10.1016/j.pharmthera.2007.08.004
Citations Scopus - 59Web of Science - 52
Co-authors Ming Yang
2007 Mattes J, Yang M, Foster PS, 'Regulation of microRNA by antagomirs: a new class of pharmacological antagonists for the specific regulation of gene function?', American Journal of Respiratory and Cellular Molecular Biology, 36 8-12 (2007) [C1]
DOI 10.1165/rcmb.2006-0227TR
Citations Scopus - 44Web of Science - 38
Co-authors Ming Yang, Paul Foster
2007 Weckmann M, Collison A, Simpson JL, Kopp MV, Wark PA, Smyth MJ, et al., 'Critical link between TRAIL and CCL20 for the activation of T(H)2 cells and the expression of allergic airway disease', Nature Medicine, 13 1308-1315 (2007) [C1]
DOI 10.1038/nm1660
Citations Scopus - 63Web of Science - 61
Co-authors Paul Foster, Nicole Hansbro, Peter Gibson, Peter Wark, Jodie Simpson
2007 Huck B, Neumann-Haefelin D, Schmitt-Graeff A, Weckmann M, Mattes J, Ehl S, Falcone V, 'Human metapneumovirus induces more severe disease and stronger innate immune response in BALB/c mice as compared with respiratory syncytial virus', Respiratory Research, 8 (2007) [C1]
DOI 10.1186/1465-9921-8-6
Citations Scopus - 17Web of Science - 19
2007 Mattes J, Whitehead BF, Liehr T, Wilkinson I, Bear J, Fagan KA, et al., 'Paternal uniparental isodisomy for chromosome 14 with mosaicism for a supernumerary marker chromosome 14', American Journal of Medical Genetics Part A, 143A 2165-2171 (2007) [C1]
DOI 10.1002/ajmg.a.31896
Citations Scopus - 11Web of Science - 11
2006 Yang M, Mattes J, Hansbro PM, Foster PS, 'Employment of microRNA profiles and RNA interference and antagomirs for the characterization and treatment of respiratory disease', Drug Discovery Today: Therapeutic Strategies, 3 325-332 (2006) [C1]
DOI 10.1016/j.ddstr.2006.10.001
Citations Scopus - 4
Co-authors Paul Foster, Philip Hansbro, Ming Yang
2005 Prescott VE, Campbell PM, Moore A, Mattes J, Rothenberg ME, Foster PS, et al., 'Transgenic expression of bean alpha-amylase inhibitor in peas results in altered structure and immunogenicity', Journal of Agricultural and Food Chemistry, 53 9023-9030 (2005) [C1]
DOI 10.1021/jf050594v
Citations Scopus - 106Web of Science - 87
Co-authors Paul Foster
2004 Clark K, Simson L, Newcombe N, Koskinen AML, Mattes J, Lee NA, et al., 'Eosinophil degranulation in the allergic lung of mice primarily occurs in the airway lumen', Journal of Leukocyte Biology, 75 1001-1009 (2004) [C1]
DOI 10.1189/jlb.0803391
Citations Scopus - 35Web of Science - 32
Co-authors Paul Foster
2004 Ihorst G, Frischer T, Horak F, Schumacher M, Kopp M, Forster J, et al., 'Long- and medium-term ozone effects on lung growth including a broad spectrum of exposure', EUROPEAN RESPIRATORY JOURNAL, 23 292-299 (2004)
DOI 10.1183/09031936.04.00021704
Citations Web of Science - 20
2004 Storm Van's Gravesande K, Mattes J, Endlicher A, Alving K, Ihorst G, Kühr J, 'Effect of two doses of budesonide on exhaled nitric oxide and urinary EPX excretion in asthmatic children', Pneumologie, 58 483-488 (2004)

The use of objective outcome measures that assess airway inflammation in pediatric asthma can provide a good evaluation of asthma severity and treatment response. In this double-b... [more]

The use of objective outcome measures that assess airway inflammation in pediatric asthma can provide a good evaluation of asthma severity and treatment response. In this double-blind and randomized study the effects of 200 µg of budesonide and 800 µg of budesonide on markers of inflammation (exhaled nitric oxide (eNO), eosinophil protein X (EPX) excretion in urine) and on lung function (FEV 1) were prospectively investigated in 24 ICS-naive children with mild persistent to moderate persistent asthma over a period of eight weeks. After eight weeks of treatment 200 µg and 800 µg of budesonide led to a significant decrease (p < 0.025) in eNO [median (90% interval): 200 µg: -17.2 ppb (-54.6 to 0.9); 800 µg: -13.2 ppb (-44.6 to -1.7)]. A significant change in urinary EPX excretion was only observed in the high dose group [200 µg: -10.3 µg/mmol creatinine (-116.2 to 50.5), p = 0.9; 800 µg: -49.2 µg/mmol creatinine (-231.0 to 48.7), p = 0.02]. However, a significant difference between the change from baseline after 8 weeks of either group was found neither for eNO (p = 0.66) nor for EPX excretion (p = 0.04). In conclusion, our data demonstrate that 800 µg budesonide per day did not show any advantage in reduction of airway inflammation, measured by eNO and urinary EPX excretion, in children with mild persistent to moderate persistent asthma.

DOI 10.1055/s-2004-818466
Citations Scopus - 3
2004 Ngoumou G, Schaefer DO, Mattes J, Kopp MV, 'Interleukin-18 enhances the production of interferon-gamma (IFN-gamma) by allergen-specific and unspecific stimulated cord blood mononuclear cells', CYTOKINE, 25 172-178 (2004)
DOI 10.1016/j.cyto.2003.11.013
Citations Web of Science - 3
2003 Mattes J, Foster P, 'Regulation of eosinophil migration and Th2 cell function by IL-5 and eotaxin', Current Drug Targets, 2 169-174 (2003) [C1]
Citations Scopus - 37
Co-authors Paul Foster
2003 Mattes J, Hulett M, Xie W, Hogan S, Rothenburg ME, Foster P, Parish C, 'Immunotherapy of cytotoxic T cell resistant tumors by T helper 2 cells: an eotaxin and STAT6 dependent process', Journal of Experimental Medicine, 197 387-393 (2003) [C1]
DOI 10.1084/jem.20021683
Citations Scopus - 112Web of Science - 107
Co-authors Paul Foster
2003 Kruse S, Kuehr J, Moseler M, Kropp MV, Kurz T, Deichmann KA, et al., 'Polymorphisms in the IL18 gene are associated with specific sensitization to common allergens and allergic rhinitis', Journal of Allergy and Clinical Immunology, 111 117-122 (2003) [C1]
DOI 10.1067/mai.2003.43
Citations Scopus - 94Web of Science - 80
Co-authors Paul Foster
2003 Lange J, Ngoumou G, Berkenheide S, Moseler M, Mattes J, Kuehr J, Kopp MV, 'High interleukin-13 production by phytohaemagglutinin- and Der p 1-stimulated cord blood mononuclear cells is associated with the subsequent development of atopic dermatitis at the age of 3 years', CLINICAL AND EXPERIMENTAL ALLERGY, 33 1537-1543 (2003)
DOI 10.1046/j.1365-2222.2003.01789.x
Citations Web of Science - 23
2002 Mattes J, Yang M, Mahalinggam S, Kuehr J, Webb DC, Simson L, et al., 'Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and cotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma.', J Exp Med. 195:1433-44, 1433-1444 (2002) [C1]
Citations Scopus - 183Web of Science - 172
Co-authors Paul Foster
2002 Mattes J, Gravesande KSV, Moeller C, Moseler M, Brandis M, Kuehr J, 'Circadian variation of exhaled nitric oxide and urinary eosinophil protein X in asthmatic and healthy children', PEDIATRIC RESEARCH, 51 190-194 (2002)
DOI 10.1203/00006450-200202000-00011
Citations Scopus - 28Web of Science - 25
2002 Foster PS, Hogan S, Yang M, Mattes J, Young I, Matthaei K, et al., 'Interleukin-5 and eosinophils as therapeutic targets for asthma', Trends in Molecular Medicine, 8 162-167 (2002) [C2]
Citations Scopus - 56Web of Science - 51
Co-authors Paul Foster
2002 Karmaus W, Arshad H, Mattes J, 'Re: "Does the sibling effect have its origin in utero? Investigating birth order, cord blood immunoglobulin E concentration, and allergic sensitization at age 4 years" - Reply', AMERICAN JOURNAL OF EPIDEMIOLOGY, 156 883-884 (2002)
DOI 10.1093/aje/kwf123
2001 Karmaus W, Arshad H, Mattes J, 'Does the sibling effect have its origin in utero? Investigating birth order, cord blood immunoglobulin E concentration, and allergic sensitization at age 4 years', AMERICAN JOURNAL OF EPIDEMIOLOGY, 154 909-915 (2001)
DOI 10.1093/aje/154.10.909
Citations Web of Science - 90
2001 Hertz M, Mahalingam S, Dalum I, Klysner S, Mattes J, Neisig A, et al., 'Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma', Journal of Immunology, 167 3792-3799 (2001) [C1]
Citations Web of Science - 66
Co-authors Paul Foster
2001 Mackenzie J, Mattes J, Dent L, Foster PS, 'Eosinophils promote allergic disease of the lung by regulating CD4+ Th2 lymphocyte function', Journal of Immunology, 167 3146-3155 (2001) [C1]
Citations Scopus - 127Web of Science - 118
Co-authors Paul Foster
2001 Mattes J, Yang M, Siqueira A, Clark K, Mackenzie J, McKenzie A, et al., 'IL-13 induces airways hyperreactivity independently of the IL-4R{alpha} chain in the allergic lung', Journal of Immunology, 167 1683-1692 (2001) [C1]
Citations Scopus - 110Web of Science - 100
Co-authors Paul Foster
2001 Foster PS, Mould A, Yang M, Mackenzie J, Mattes J, Hogan S, et al., 'Elemental signals regulating eosinophil accumulation in the lung', Immunological Reviews, 179 173-181 (2001) [C2]
Citations Scopus - 160Web of Science - 145
Co-authors Paul Foster
2000 Webb D, McKenzie A, Koskinen A, Yang M, Mattes J, Foster PS, 'Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity', Journal of Immunology, 165 108-113 (2000) [C1]
Citations Scopus - 216Web of Science - 194
Co-authors Paul Foster
2000 Mattes J, van's Gravesande KS, Moeller C, Kuehr J, 'Circadian variation of urinary EPX in asthmatic and healthy children', JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 105 S193-S193 (2000)
DOI 10.1016/S0091-6749(00)91008-X
2000 van Gravesande KS, Mattes J, Grossklauss E, Zurmuhl A, Moseler M, Kuhr J, 'Preventive effect of 2 and 10 mg of sodium cromoglycate on exercise-induced bronchoconstriction', EUROPEAN JOURNAL OF PEDIATRICS, 159 759-763 (2000)
Citations Scopus - 8Web of Science - 1
2000 Reining U, Mattes J, Storm van's Gravesande K, Ihorst G, Kühr J, '[Reproducibility in induced sputum in children with asthma]', Pneumologie (Stuttgart, Germany), 54 185-190 (2000)
DOI 10.1055/s-2000-3828
1999 Mattes J, Gravesande KS, Reining U, Alving K, Ihorst G, Henschen M, Kuehr J, 'NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma', EUROPEAN RESPIRATORY JOURNAL, 13 1391-1395 (1999)
DOI 10.1183/09031936.99.13613969
Citations Scopus - 117Web of Science - 97
1999 Mattes J, Karmaus W, 'The use of antibiotics in the first year of life and development of asthma: which comes first?', CLINICAL AND EXPERIMENTAL ALLERGY, 29 729-732 (1999)
Citations Web of Science - 19
1999 van's Gravesande KS, Mattes J, Gruntjens T, Kopp M, Seydewitz HH, Moseler M, Kuehr J, 'Circadian variation of urinary eosinophil protein X in asthmatic and healthy children', CLINICAL AND EXPERIMENTAL ALLERGY, 29 1497-1501 (1999)
Citations Scopus - 17Web of Science - 11
1999 Bohnet W, Bar G, Strauch E, Ihorst G, Mattes J, Schneider C, et al., 'Short-term effect of particular matter (PM10) on pulmonary function in schoolchildren over two years', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 159 A772-A772 (1999)
1999 Mattes J, Baer G, Schneider C, Bohnet W, Ihorst G, Strauch E, et al., 'Association between respiratory symptoms and ambient ozone levels over two summers in 765 schoolchildren', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 159 A772-A772 (1999)
1999 Mattes J, Baer G, Schneider C, Bohnet W, Ihorst G, Strauch E, et al., 'Correlation between personal and fixed-site ozone measurements in schoolchildren', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 159 A772-A772 (1999)
1999 Mattes J, van Gravesande KS, Reining U, Alving K, Ihorst G, Heuschen M, Kuehr J, 'Nitric oxide in exhaled air is correlated with eosinophilic airway inflammation in children with chronic asthma', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 159 A862-A862 (1999)
1999 Gravesande KSV, Langenbacher E, Mattes J, Zurmuehl A, Beck W, Moseler M, Knehr J, 'Sodium cromoglycate (SCG) reduces the excretion of eosinophil protein X (EPX) in children with exercise induced asthma', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 159 A911-A911 (1999)
1999 Mattes J, Karmaus W, Gravesande KSV, Moseler M, Forster J, Kuehr J, 'Pulmonary function in children of school age is related to the number of siblings in their family', PEDIATRIC PULMONOLOGY, 28 414-417 (1999)
DOI 10.1002/(SICI)1099-0496(199912)28:6<414::AID-PPUL5>3.0.CO;2-K
Citations Web of Science - 7
1998 Mattes J, Karmaus W, Moseler M, Frischer T, Kuehr J, 'Accumulation of atopic disorders within families: a sibling effect only in the offspring of atopic fathers', CLINICAL AND EXPERIMENTAL ALLERGY, 28 1480-1486 (1998)
Citations Scopus - 19Web of Science - 21
Show 73 more journal articles

Review (2 outputs)

Year Citation Altmetrics Link
2013 Plank M, Maltby S, Mattes J, Foster PS, 'Targeting translational control as a novel way to treat inflammatory disease: The emerging role of MicroRNAs', Clinical and Experimental Allergy (2013) [C1]

Chronic inflammatory diseases (e.g. asthma and chronic obstructive pulmonary disease) are leading causes of morbidity and mortality world-wide and effective treatments are limited... [more]

Chronic inflammatory diseases (e.g. asthma and chronic obstructive pulmonary disease) are leading causes of morbidity and mortality world-wide and effective treatments are limited. These disorders can often be attributed to abnormal immune responses to environmental stimuli and infections. Mechanisms leading to inflammation are complex, resulting from interactions of structural cells and activation of both the adaptive and innate arms of the immune system. The activation of structural and immune cells involves both temporary and permanent changes in gene expression in these cells, which underpin chronic inflammation and tissue dysfunction. miRNAs are small non-coding RNAs increasingly being recognized to play important roles in the post-transcriptional regulation of gene expression in mammalian cells by regulating translation. Individual miRNAs can exert their effects by directly inhibiting the translation or stability of multiple mRNAs simultaneously. Thus, the expression or blockade of function of a single miRNA (miR) can result in pronounced alterations in protein expression within a given cell. Dysregulation of miRNA expression may subsequently alter cellular function, and in certain situations predispose to disease. Our current understanding of the role of miRNA in the regulation of inflammatory disease (e.g. allergic diseases) remains limited. In this review, we provide an overview of the current understanding of miRNA biogenesis and function, the roles miRNA play in the regulation of immune cell function and their potential contribution to inflammatory diseases. We also highlight strategies to alter miRNA function for experimental or therapeutic gain, and discuss the potential utility and limitations of targeting these molecules as anti-inflammatory strategies. © 2013 John Wiley & Sons Ltd.

DOI 10.1111/cea.12135
Citations Scopus - 8Web of Science - 6
Co-authors Steven Maltby, Paul Foster
2013 Plank M, Maltby S, Mattes J, Foster PS, 'Targeting translational control as a novel way to treat inflammatory disease: the emerging role of microRNAs.', Clinical and Experimental Allergy (2013) [C1]
DOI 10.1111/cea.12170
Co-authors Steven Maltby, Paul Foster

Conference (37 outputs)

Year Citation Altmetrics Link
2015 Kim R, Horvat J, Pinkerton J, Starkey M, Essilfie A, Mayall J, et al., 'INFECTION-INDUCED MICRORNA-21 DRIVES SEVERE, STEROID-INSENSITIVE EXPERIMENTAL ASTHMA BY AMPLIFYING PI3K-MEDIATED SUPPRESSION OF HDAC2', RESPIROLOGY (2015)
Co-authors Philip Hansbro
2015 Tay H, Kaiko G, Plank M, Li J, Essilfie A, Maltby S, et al., 'THE ROLE OF MIR-328 IN RESPIRATORY DISEASES', RESPIROLOGY (2015)
Co-authors Philip Hansbro, Steven Maltby
2014 Mandaliya PH, Bhatia R, Belcher J, McElduff P, Collison A, Mattes J, 'Is fraction of exhaled nitric oxide (FeNO) able to predict severity of allergic reaction at an open cooked egg challenge?', ALLERGY, Copenhagen, DENMARK (2014) [E3]
Co-authors Patrick Mcelduff
2014 Collison A, Hatchwell L, Girkin J, Li J, Parsons K, Bartlett N, et al., 'REDUCED TLR7 EXPRESSION MAY UNDERPIN IMPAIRED RESPONSE TO VIRAL INFECTION IN ASTHMA', RESPIROLOGY (2014) [E3]
DOI 10.1111/resp.12263_5
Co-authors Paul Foster, Peter Wark
2014 Li J, Collison A, De Siqueira PA, Zhang J, Mattes J, 'TUMOUR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND (TRAIL) REGULATION OF PROTEIN PHOSPHATASE (PP)2A IS CRUCIAL FOR THE DEVELOPMENT OF BLEOMYCIN INDUCED PULMONARY FIBROSIS IN MICE', RESPIROLOGY (2014) [E3]
2014 Preece K, Bhatia R, Belcher J, Patchett K, Mcelduff P, Collison A, Mattes J, 'FRACTION OF EXHALED NITRIC OXIDE IS A NOVEL NON-INVASIVE PREDICTOR OF PEANUT ALLERGY', RESPIROLOGY (2014) [E3]
Co-authors Patrick Mcelduff
2014 Rhys-Jones B, Bhatia R, Hilton J, Kumar R, Mattes J, 'RECURRENT, THERAPY-RESISTANT ALVEOLAR INFILTRATES IN A YOUNG CHILD: APPROACHES TO DIAGNOSIS AND CHALLENGES IN MANAGEMENT', RESPIROLOGY (2014) [E3]
2014 Girkin J, Sokulsky L, Hatchwell L, Starkey M, Collison A, Hansbro P, Mattes J, 'IDENTIFICATION OF A NOVEL INTERLEUKIN-13 SIGNALLING PATHWAY', RESPIROLOGY (2014) [E3]
Co-authors Malcolm Starkey, Philip Hansbro
2013 Preece KD, Bhatia R, Belcher J, Patchett K, McElduff P, Mattes J, 'Prospective validation and accuracy of Ara h2 in the diagnosis of childhood peanut allergy', ALLERGY, Milan, ITALY (2013) [E3]
Co-authors Patrick Mcelduff
2013 Girkin J, Hatchwell L, Foster PS, Johnston SL, Collison A, Mattes J, 'SALMETEROL ATTENUATES CHEMOTAXIS IN RHINOVIRUS-INDUCED EXACERBATION OF ASTHMA VIA MODULATION OF PP2A', RESPIROLOGY (2013) [E3]
Co-authors Paul Foster
2013 Mattes J, Murphy V, Powell H, Gibson P, 'THE EFFECT OF BETTER ASTHMA CONTROL IN PREGNANCY ON WHEEZY ILLNESSES IN INFANCY', RESPIROLOGY (2013) [E3]
Citations Web of Science - 1
Co-authors Peter Gibson, Vanessa Murphy
2013 Gunawardhana LP, Baines KJ, Mattes J, Murphy VE, Simpson JL, Gibson PG, 'EPIGENETIC ALTERATIONS IN INFANTS ASSOCIATED WITH MATERNAL ASTHMA DURING PREGNANCY', RESPIROLOGY (2013) [E3]
Co-authors Peter Gibson, Katherine Baines, Jodie Simpson, Vanessa Murphy
2013 Hatchwell L, Collison A, Phipps S, Foster PS, Johnston SL, Mattes J, 'CCL7 (MCP-3) MEDIATES RHINOVIRUS-INDUCED LUNG INFLAMMATION AND EXACERBATION OF ALLERGIC AIRWAY DISEASE', RESPIROLOGY (2013) [E3]
Co-authors Paul Foster
2012 Starkey M, Kim R, Horvat J, Essilfie A-T, Beagley K, Mattes J, et al., 'Constitutive IL-13 promotes respiratory chlamydial infection and infection-induced chronic airway hyper-responsiveness', JOURNAL OF IMMUNOLOGY, Boston, MA (2012) [E3]
Co-authors Paul Foster, Philip Hansbro
2012 Collison AM, Hatchwell LM, Siqueira AP, Bartlett NW, Johnston SL, Foster PS, Mattes J, 'Antagonism of microRNA-122 is comparible to azithromycin treatment in a mouse model of rhinovirus-induced exacerbation of allergic airways disease', Respirology, Canberra, ACT (2012) [E3]
Co-authors Paul Foster
2012 Hatchwell LM, Collison AM, Siqueira AP, Bartlett NW, Johnston SL, Foster PS, Mattes J, 'Toll-like receptor 7 mediates anti-viral responses to rhinovirus while suppressing exacerbation of asthma', Respirology, Canberra, ACT (2012) [E3]
Co-authors Paul Foster
2012 Hatchwell LM, Collison AM, Siqueira AP, Bartlett NW, Johnston SL, Foster PS, Mattes J, 'TRAIL regulates inflammatory responses to rhinovirus and rhinovirus-induced exacerbation of asthma', Respirology, Canberra, ACT (2012) [E3]
Co-authors Paul Foster
2012 Plank MW, Kaiko GE, Luck H, Li J, Mattes J, Hansbro PM, Foster PS, 'The role of micrornas in CD4 T cell function', Respirology, Canberra, ACT (2012) [E3]
Co-authors Paul Foster, Philip Hansbro
2012 Starkey MR, Kim RY, Horvat JC, Essilfie A-T, Beagley KW, Mattes J, et al., 'Constitutive IL-13 promotes respiratory chlamydial infection-induced chronic airway hyperresponsiveness', Respirology, Canberra, ACT (2012) [E3]
Co-authors Jay Horvat, Malcolm Starkey, Philip Hansbro, Paul Foster
2012 Tay HL, Kaiko GE, Plank MW, Mattes J, Hansbro PM, Foster PS, 'MiRNAs regulate bacterial infection in lungs', Respirology, Canberra, ACT (2012) [E3]
Co-authors Philip Hansbro, Paul Foster
2011 Foster PS, Tay HL, Kaiko GE, Plank MW, Mattes J, Hansbro PM, 'MiRNA and its roles in regulating bacterial infection in lungs', American Journal of Respiratory and Critical Care Medicine, Denver, CO (2011) [E3]
Co-authors Philip Hansbro, Paul Foster
2011 McLaughlin KM, Mattes J, Murphy VE, Steel KR, Powell H, Gibson PG, 'The Growing Into Asthma (GIA) Study: Need for improved management of respiratory illnesses in early life', PSANZ 2011 15th Annual Congress: Poster Abstracts, Hobart, TAS (2011) [E3]
Co-authors Peter Gibson, Vanessa Murphy
2011 Gunawardhana LP, Baines KJ, Simpson JL, Mattes J, Murphy VE, Gibson PG, 'Maternal asthma is associated with alterations in DNA methylation profile of peripheral blood of infants', Respirology, Perth, WA (2011) [E3]
Co-authors Jodie Simpson, Vanessa Murphy, Peter Gibson, Katherine Baines
2011 Mattes J, Murphy VE, McLaughlin KM, Steel KR, Powell H, Gibson PG, 'Are maternal asthma exacerbations during pregnancy related to impaired infant growth in the first six months of life?', Respirology, Perth, WA (2011) [E3]
Co-authors Vanessa Murphy, Peter Gibson
2011 Collison AM, Hatchwell LM, Pereira De Siqueira AL, Don A, Verrills NM, Foster PS, Mattes J, 'The development of house dust mite-induced allergic airways disease is regulated by a novel E3 ubiquitin ligase-dependent deactivation of a protein phosphatase', Respirology, Perth, WA (2011) [E3]
Co-authors Nikki Verrills, Paul Foster
2011 Hatchwell LM, Collison AM, Pereira De Siqueira AL, Foster PS, Verrills NM, Don A, et al., 'A novel E3 ubiquitin ligase links rhinovirus infection to exacerbation of asthma', Respirology, Perth, WA (2011) [E3]
Co-authors Peter Wark, Nikki Verrills, Paul Foster
2011 Mattes J, Hankin RG, Hilton JM, Collison AM, Pereira De Siqueira AL, Gulliver T, et al., 'Frequent persistent wheeze in infancy may be associated with impaired FEV0.5 and FVC values', Respirology, Perth, WA (2011) [E3]
Co-authors Paul Foster
2010 Ptaschinski CM, Phipps S, Hansbro NG, Rosenberg HF, Mattes J, Foster PS, 'MicroRNAs are involved in the regulation of inflammatory responses characteristic of severe respiratory virus infection', American Journal of Respiratory and Critical Care Medicine, New Orleans (2010) [E3]
Co-authors Nicole Hansbro, Paul Foster
2010 Mattes J, Collison AM, Plank MW, Phipps S, Foster PS, 'The role of microRNA as new anti-inflammatory targets', APCAACI 2010: The 8th Asia Pacific Congress on Allergy, Asthma and Clinical Immunology Programme & Abstracts Handbook, Singapore (2010) [E3]
Co-authors Paul Foster
2010 Foster PS, Mattes J, Collison AM, Plank MW, Phipps S, 'MicoRNAs bridge innate and adative immunity: induction of TH2 mediated allergic airways disease', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Abstracts, Melbourne, Vic (2010) [E3]
Co-authors Paul Foster
2009 Collison AM, Mattes J, Phipps S, Plank MW, Foster PS, 'MicroRNAs are crucial in the development of airways hyperreactivity', American Journal of Respiratory and Critical Care Medicine, San Diego, CA (2009) [E3]
Co-authors Paul Foster
2009 Mattes J, Collison AM, Plank MW, Phipps S, Foster PS, 'MicroRNAs regulate allergic airway inflammation', American Journal of Respiratory and Critical Care Medicine, San Diego, CA (2009) [E3]
Co-authors Paul Foster
2009 Collison AM, De Siqueira A, Plank MW, Foster PS, Mattes J, 'The identification of TRAIL as a mediator of airways remodelling in a chronic model of murine allergic airways disease', American Journal of Respiratory and Critical Care Medicine, San Diego, CA (2009) [E3]
Co-authors Paul Foster
2007 Talbot PI, Wright IM, Hilton JM, Mattes J, Clifton VL, 'Effect of maternal asthma during pregnancy on childhood growth and development of atopic disease', Respirology (TSANZ Abstracts-Posters), Auckland (2007) [E3]
Co-authors Ian Wright, Vicki Clifton
2006 Mattes J, Simpson JL, Foster PS, Gibson PG, 'Trail is upregulated in the airways of asthmatics', Respirology, Canberra (2006) [E3]
Co-authors Paul Foster, Peter Gibson, Jodie Simpson
2002 Klysner S, Mahalingam S, Neisig A, Hertz M, Dalum I, Mattes J, et al., 'Induction of a protective immune response in a murine model of asthma by DNA vaccination with modified IL-5', ALLERGY, NAPLES, ITALY (2002)
2002 Lange J, Schaefer D, Engels E, Mattes J, Kuehr J, Kopp M, 'Interferon-gamma and IL-13 production in response to PHA and IL-18 by human cord blood mononuclear cells', ALLERGY, NAPLES, ITALY (2002)
Citations Web of Science - 1
Show 34 more conferences
Edit

Grants and Funding

Summary

Number of grants 42
Total funding $9,953,845

Click on a grant title below to expand the full details for that specific grant.


20154 grants / $1,239,402

The effect of asthma control during pregnancy on markers of airways inflammation and lung function in the offspring$1,083,354

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Joerg Mattes, Doctor Vanessa Murphy, Professor Peter Sly, Doctor Adam Collison, Professor Paul Robinson
Scheme Project Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1400050
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Improving diet quality to reduce risk of asthma attacks in children$120,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Lisa Wood, Professor Joerg Mattes, Conjoint Professor Peter Wark, Doctor Katie Baines, Miss Megan Jensen
Scheme Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500957
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Viral infections in the BLT cohort in the first year of life$19,000

Funding body: John Hunter Hospital Charitable Trust Fund

Funding body John Hunter Hospital Charitable Trust Fund
Project Team Professor Joerg Mattes, Doctor Vanessa Murphy, Doctor Adam Collison
Scheme Research Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1500671
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Lung function in early life for children with high asthma risk$17,048

Funding body: Rebecca L Cooper Medical Research Foundation Ltd

Funding body Rebecca L Cooper Medical Research Foundation Ltd
Project Team Professor Joerg Mattes, Doctor Vanessa Murphy, Doctor Adam Collison
Scheme Research Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1500704
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20146 grants / $2,382,182

The Breathing for Life Trial $1,647,904

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Vanessa Murphy, Conjoint Professor Peter Gibson, Emeritus Professor Michael Hensley, Professor Joerg Mattes, Professor Warwick Giles, Professor Michael Peek, Associate Professor Andrew Bisits, Associate Professor Leonie Callaway, Dr Kirsten McCaffery, Dr Helen Barrett
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1300106
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Toll-like receptor 7 and asthma $673,712

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Joerg Mattes, Laureate Professor Paul Foster, Conjoint Professor Peter Wark
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1300093
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

High-flow Nasal-prong Warm Humidified Oxygen Pilot Randomised Control Trial for infants aged = 24 months with moderate bronchiolitis$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Mrs Elizabeth Kepreotes, Professor Joerg Mattes
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301430
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Miltenyi Biotec GentleMACS Octo Dissociator with Heaters $23,566

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Professor Darryl Knight, Professor Dirk Van Helden, Professor Joerg Mattes, Associate Professor Jodie Simpson, Associate Professor Lisa Wood, Associate Professor Liz Milward, Dr NATHAN Bartlett, Doctor Simon Keely, Doctor Steven Maltby, Doctor Andrew Jarnicki, Doctor Malcolm Starkey, Doctor Adam Collison, Ms Shaan Gellatly
Scheme Equipment Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1500861
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

A descriptive observational study of infants aged < 24 months with severe bronchiolitis requiring critical care$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Mrs Elizabeth Kepreotes, Professor Joerg Mattes, Doctor Peter Harrigan, Conjoint Associate Professor Bruce Whitehead, Professor John Attia, Doctor Mark Lee
Scheme Critical Care and HMRI BRICs Nursing Research and Innovation Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1401451
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

European Respiratory Congress (ERS) 2014, ICM - International Congress Centre, Munich Germany, 6 - 10 September 2014$2,000

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Professor Joerg Mattes
Scheme Travel Grant
Role Lead
Funding Start 2014
Funding Finish 2015
GNo G1401074
Type Of Funding Internal
Category INTE
UON Y

20136 grants / $163,959

Asthma Australia Scholarship$73,959

Funding body: Asthma Australia

Funding body Asthma Australia
Project Team Professor Joerg Mattes
Scheme National Research Program (PhD Scholarship)
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1300552
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Molecular and cellular characterisation of TLR7 signalling in rhinovirus-induced asthma exacerbation$25,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Joerg Mattes
Scheme Near Miss Grant
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1300469
Type Of Funding Internal
Category INTE
UON Y

Molecular and cellular characterisation of TLR7 signalling in rhinovirus-induced asthma exacerbation$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Joerg Mattes, Laureate Professor Paul Foster
Scheme Near Miss
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1300692
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

DP73 Digital colour and monochrome camera + cellSens software + Xcite120 fluorescence lamp illuminator$20,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Doctor Alan Hsu, Professor Phil Hansbro, Professor Joerg Mattes, Doctor Katie Baines, Associate Professor Jodie Simpson, Professor Rakesh Kumar, Doctor Nicole Hansbro, Doctor Steven Maltby, Doctor Ming Yang, Doctor Gerard Kaiko, Doctor Jay Horvat, Doctor Simon Keely, Doctor Andrew Jarnicki, Doctor Michael Fricker
Scheme Equipment Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1201186
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Effect of better asthma management in pregnancy on antiviral responses, atopy and airways inflammation in early childhood$10,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Joerg Mattes, Conjoint Professor Peter Gibson, Doctor Vanessa Murphy
Scheme Near Miss Grant
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1300476
Type Of Funding Internal
Category INTE
UON Y

Effect of better asthma management in pregnancy on antiviral responses, atopy and airways inflammation in early childhood.$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Joerg Mattes, Conjoint Professor Peter Gibson, Doctor Vanessa Murphy
Scheme Near Miss
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1300694
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20125 grants / $135,000

SpectraMax M5e Multi-Mode Microplate Reader$50,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Professor Phil Hansbro, Professor Joerg Mattes, Professor Rakesh Kumar, Doctor Nicole Hansbro, Doctor Ming Yang, Doctor Jay Horvat, Doctor Simon Keely, Doctor Andrew Jarnicki, Doctor Linda Howland, Doctor Kelly Asquith
Scheme Equipment Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1100975
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

The Growing into Asthma Study: Wheezing prevalence and markers of airways inflammation in preschoolers born to mothers in asthma exacerbations in pregnancy$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Joerg Mattes, Conjoint Professor Peter Gibson, Emeritus Professor Michael Hensley, Conjoint Associate Professor Bruce Whitehead, Doctor Vanessa Murphy
Scheme Project Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200662
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Novel molecular markers in children with eosinophilic oesophagitis – association with symptoms, oesophageal function and treatment response and role in disease pathogenesis$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Scott Nightingale, Professor Joerg Mattes, Doctor Adam Collison, Laureate Professor Nick Talley
Scheme Project Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1200661
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Coordinated targeting of immune pathways to suppress infection-associated inflammatory diseases.$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro, Professor Joerg Mattes
Scheme Near Miss Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1200671
Type Of Funding Internal
Category INTE
UON Y

Molecular and cellular characterisation of TLR7 signalling for the expression of rhinovirus induced asthma exacerbation$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Joerg Mattes
Scheme Near Miss Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200680
Type Of Funding Internal
Category INTE
UON Y

20114 grants / $1,313,780

Targeting microRNA (miRNA) as a unified therapeutic approach to the treatment of asthma and allergic inflammation$651,732

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Professor Joerg Mattes, Professor Rakesh Kumar
Scheme Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1000262
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Molecular characterisation of TRAIL-regulated signal transduction pathways and their role in the development, persistence, and exacerbation of allergic airways disease$615,048

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Joerg Mattes, Doctor Nikki Verrills
Scheme Project Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1000314
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

SCIREQ FlexiVentFX system + FlexiVentFX extension$45,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Professor Joerg Mattes, Doctor Simon Keely, Doctor Jay Horvat, Doctor Nicole Hansbro, Doctor Ming Yang, Doctor Catherine Ptaschinski, Doctor Kelly Asquith, Doctor Gough Au, Conjoint Professor Peter Wark, Laureate Professor John Aitken, Conjoint Professor Keith Jones, Professor Roger Smith, Professor Judith Black, Professor Rakesh Kumar, Professor Paul Hertzog
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100037
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

7th IES Syumposium, 21 - 25 June 2011, Quebec City$2,000

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Professor Joerg Mattes
Scheme Travel Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1100834
Type Of Funding Internal
Category INTE
UON Y

20103 grants / $642,342

The role of microRNAs in the regulation of antiviral and inflammatory responses during experimental rhinovirus infection$583,500

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Joerg Mattes, Laureate Professor Paul Foster
Scheme Project Grant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G0190183
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Buxco FinePointe software and FinePointe RC system for mice $39,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Professor Phil Hansbro, Professor Joerg Mattes, Doctor Nicole Hansbro, Doctor Simon Phipps, Doctor Ming Yang, Doctor Kelly Asquith, Doctor Catherine Ptaschinski, Professor Rakesh Kumar, Professor Judith Black
Scheme Equipment Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G1000053
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Molecular markers of reversible airway obstruction in early life and correlation with clinical wheezing patterns$19,842

Funding body: Hunter Children`s Research Foundation

Funding body Hunter Children`s Research Foundation
Project Team Professor Joerg Mattes, Laureate Professor Paul Foster, Conjoint Associate Professor Bruce Whitehead, Doctor Ana Pereira De Siqueira
Scheme Research Grant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G0900119
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20098 grants / $733,575

Mechanisms and treatment of early life chlamydial infection and associated asthma$592,125

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Professor Kenneth Beagley, Professor Joerg Mattes
Scheme Project Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0188845
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Coulter counter$41,150

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Professor Phil Hansbro, Professor Joerg Mattes, Doctor Simon Phipps, Doctor Ming Yang, Doctor Nicole Hansbro, Doctor Kelly Asquith
Scheme Equipment Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0189851
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Jaeger MasterScreen Baby Bodybox for infant lung function measurement$30,000

Funding body: Ramaciotti Foundations

Funding body Ramaciotti Foundations
Project Team Professor Joerg Mattes
Scheme Major Equipment Award
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0189323
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Growing into asthma: A birth cohort study to investigate the prenatal and development origins of asthma$24,800

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Vanessa Murphy, Professor Joerg Mattes, Conjoint Professor Peter Gibson
Scheme Project Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0189802
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Development of novel therapeutic approaches for rhinovirus - induced asthma exacerbation$24,500

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Joerg Mattes, Laureate Professor Paul Foster, Conjoint Professor Peter Wark
Scheme Project Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0189800
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Growing into asthma: a birth cohort study to investigate the prenatal and development origins of asthma$13,500

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Vanessa Murphy, Professor Joerg Mattes, Conjoint Professor Peter Gibson
Scheme Project Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0190487
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Small RNA molecules and Rhinovirus$5,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Joerg Mattes
Scheme New Staff Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0190605
Type Of Funding Internal
Category INTE
UON Y

American Thoracic Society Annual meeting, San Diego USA, 15 - 20 May 2009$2,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Professor Joerg Mattes
Scheme Travel Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0190138
Type Of Funding Internal
Category INTE
UON Y

20082 grants / $635,375

The role of microRNAs as new anti-inflammatory targets for the treatment of asthma$600,375

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Professor Rakesh Kumar, Assoc. Prof Klaus Matthaei, Professor Joerg Mattes
Scheme Project Grant
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo G0187584
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Individually ventilated cages (IVC) and associated ventilator, holding boxes and water bottles$35,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Professor Phil Hansbro, Professor Joerg Mattes, Doctor Simon Phipps, Doctor Ming Yang, Doctor Nicole Hansbro, Doctor Kelly Asquith
Scheme Equipment Grant
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo G0188541
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20071 grants / $137,000

Molecular mechanisms of persistent allergic responses$137,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Joerg Mattes
Scheme Training (Postdoctoral) Fellowships - Health Professional Research Fellowship (Part-time)
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0186769
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

20062 grants / $540,282

PRC Priority Research Centre for Asthma & Respiratory Diseases$524,282

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Laureate Professor Paul Foster, Conjoint Professor Peter Gibson, Conjoint Professor Kenneth Beagley, Emeritus Professor Michael Hensley, Professor Phil Hansbro, Professor Joerg Mattes, Professor Alistair Sim, Conjoint Professor Peter Wark
Scheme Priority Research Centre
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo G0186914
Type Of Funding Internal
Category INTE
UON Y

Role of TRAIL on development of atopic dermatitis and T helper type 2 immunity$16,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Joerg Mattes, Laureate Professor Paul Foster
Scheme Project Grant
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186098
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20051 grants / $2,030,948

Drug targets from new animal models$2,030,948

Funding body: CRC for Asthma

Funding body CRC for Asthma
Project Team Laureate Professor Paul Foster, Professor Phil Hansbro, Professor Joerg Mattes, Doctor Ming Yang, Dr Simon Phipps
Scheme Research Grant
Role Investigator
Funding Start 2005
Funding Finish 2005
GNo G0185860
Type Of Funding CRC - Cooperative Research Centre
Category 4CRC
UON Y
Edit

Research Supervision

Number of supervisions

Completed3
Current10

Total current UON EFTSL

PhD4.75

Current Supervision

Commenced Level of Study Research Title / Program / Supervisor Type
2015 PhD Novel Signalling Pathways in Food Allergy and Eosinophilic Oesophagitis
Microbiology, Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2015 PhD Post-Transitional Cardiac Physiology in Very Preterm Neonates
Paediatrics, Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2015 PhD PEAnut Anaphylaxis Predictors (PEAAP study)
General Medicine, Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2015 PhD PEAnut Anaphylaxis Predictors (PEAAP study)
Paediatrics, Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2014 PhD To Determine the Effect of Reduced Asthma Exacerbations During Pregnancy on Markers of Airways Inflammation, Lung Function, and Antiviral Responses in the Offspring at Six Years of Age
General Medicine, Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2013 PhD The Impact of Better Asthma Management during Pregnancy on the Lung Function of the Child
Paediatrics, Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2012 PhD The Role of Rhinovirus, TRAIL, IL-13 and PP2A in Allergic Airways Disease
Microbiology, Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2012 PhD The Role of TRAIL in the Induction and Perpetuation of Eosinophilic Oesophagitis
Paediatrics, Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2012 PhD Understanding the mechanisms of airway hyper-responsiveness in a mouse model of asthma
Microbiology, Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2010 PhD Role of TRAIL and TLRT in Response to Rhinovirus Infection in Allergic Airways Disease
Microbiology, Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor

Past Supervision

Year Level of Study Research Title / Program / Supervisor Type
2014 PhD The Role of microRNAs in Allergic Airways Disease and T Cell Biology
Microbiology, Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2014 PhD The Role of MicroRNA in Regulating Anti-Bacterial Responses in Innate Immune Cells
Microbiology, Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2012 PhD Novel Therapeutic Approaches for the Treatment of Allergic Airways Disease
Microbiology, Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
Edit

News

HMRI logo

Asthma researchers' virus and allergy breakthrough

January 21, 2013

Paediatric and respiratory researchers from the University of Newcastle, along with national and international collaborators, are a step closer to identifying the source of serious virus-and allergen-induced asthma attacks after detecting important molecular signals generated very early in the disease process.

Professor Joerg Mattes

Position

Chair - Paediatrics & Child Health
Experimental&Translational Respiratory Group
School of Medicine and Public Health
Faculty of Health and Medicine

Focus area

Immunology and Microbiology

Contact Details

Email joerg.mattes@newcastle.edu.au
Phone (02) 40420209 (02) 49213656
Fax (02) 49855277 (02) 40420023

Office

Room 2411
Building HMRI
Location Level 2 East, HMRI, Lot 1 Kookaburra Circuit, New Lambton Heights, NSW 2305, Australia

,
Edit